ACE-031 UK Research Protein for Advanced Myostatin Inhibition Applications
ACE-031 UK research protein is one of the most extensively characterised ActRIIB-based myostatin inhibitors within musculoskeletal, anabolic-signalling and TGF-β pathway research literature. At Lavish Peptides, we supply premium-quality ACE-031 products for laboratory and in vitro research applications throughout the United Kingdom and Europe, including London, Manchester, Birmingham, Liverpool, Leeds, Glasgow, Edinburgh, Dublin, Paris, Berlin, Amsterdam, Madrid, Milan and Rome.
ACE-031, also known as Ramatercept, ACVR2B/Fc and soluble ActRIIB, is a recombinant fusion protein comprising the extracellular domain of activin receptor type IIB (ActRIIB / ACVR2B) linked to a human IgG1-Fc region. Scientific investigations have identified ACE-031 as one of the most important broad-spectrum ActRIIB ligand traps developed for research into skeletal-muscle hypertrophy, myostatin signalling and musculoskeletal biology.
Research literature has characterised ACE-031 as a soluble decoy receptor engineered to bind and neutralise multiple TGF-β superfamily ligands including myostatin (GDF-8), activin A, activin B, GDF-11 and BMP-family ligands before they can activate endogenous membrane-bound ActRIIB receptors. Published investigations documented that this broad ligand sequestration profile produces substantially greater anabolic signalling effects than myostatin-specific antibodies alone.
Scientific investigations have additionally demonstrated that ACE-031 suppresses canonical SMAD2/3 signalling, thereby relieving inhibition of the PI3K/Akt/mTOR anabolic pathway responsible for muscle protein synthesis, hypertrophy and satellite-cell activation. Research literature further documented substantial effects on lean mass, bone mineral density and adipokine modulation across pre-clinical and early clinical investigations.
Each ACE-031 UK vial supplied by Lavish Peptides is produced according to strict laboratory-focused standards and supplied as a lyophilised powder in sealed laboratory-grade vials designed to support product integrity during transport and storage. Every batch undergoes third-party HPLC and mass spectrometry analytical verification procedures to support high purity and consistency expectations for laboratory and analytical applications.
Researchers throughout England, Scotland, Ireland, Germany, France, Spain, Italy, the Netherlands, Belgium, Austria, Portugal and wider Europe increasingly seek trusted peptide suppliers capable of combining premium sourcing standards with dependable fulfilment procedures and discreet shipping services. Lavish Peptides continues supporting laboratories and musculoskeletal researchers throughout the UK and Europe with premium peptide compounds and professional customer support.
Researchers interested in exploring additional premium peptide compounds can also browse our full peptide collection through the Lavish Peptides online catalogue.
Premium ACE-031 UK Laboratory Standards
At Lavish Peptides, quality assurance remains central to every peptide product supplied throughout the UK and Europe. Every ACE-031 UK batch undergoes third-party HPLC and mass spectrometry verification procedures designed to support analytical purity and consistency expectations for laboratory and in vitro research use.
The fusion protein is supplied within sealed amber laboratory vials intended to help minimise unnecessary environmental exposure during transport and storage. Orders are processed using discreet packaging and secure fulfilment procedures for customers throughout London, Manchester, Birmingham, Glasgow, Edinburgh, Paris, Berlin, Amsterdam, Madrid and Milan.
Researchers throughout England, Ireland, France, Germany, Spain and Italy continue seeking reliable peptide suppliers capable of delivering premium-quality myostatin inhibitor research compounds with dependable shipping and transparent fulfilment standards. Lavish Peptides remains committed to supporting peptide researchers throughout Europe with premium peptide products and responsive customer support.
As anabolic-signalling and musculoskeletal research continue expanding internationally, laboratories increasingly prioritise suppliers with strong quality-control standards and reliable fulfilment operations. Our objective is to provide premium peptide sourcing for research-focused customers across the UK and European peptide market.
Scientific Interest in ACE-031 UK Research
ACE-031 UK research continues receiving substantial attention within peptide-science literature and laboratory investigations involving myostatin inhibition, ActRIIB signalling and musculoskeletal-pathway analysis.
Research involving ACE-031 has discussed:
- Myostatin (GDF-8) neutralisation and ActRIIB signalling
- Activin A/B and GDF-11 ligand sequestration
- SMAD2/3 suppression and PI3K/Akt/mTOR activation
- Skeletal-muscle hypertrophy and hyperplasia studies
- Bone mineral density and osteoblast/osteoclast research
- Duchenne muscular dystrophy and cachexia models
- Fat metabolism and adipokine modulation
- BMP-9/BMP-10 endothelial signalling investigations
Published scientific investigations have demonstrated that ACE-031 functions as a broad-spectrum ActRIIB ligand trap capable of producing substantial fibre type-independent skeletal-muscle hypertrophy. Research literature additionally documented that soluble ActRIIB receptor systems produce significantly greater anabolic effects than myostatin-specific monoclonal antibodies alone, confirming additive contributions from activin A and GDF-11 signalling pathways.
Scientific literature has additionally confirmed that ACE-031 suppresses canonical SMAD2/3 signalling, relieving transcriptional inhibition of anabolic muscle genes and permitting increased activity of the PI3K/Akt/mTOR pathway associated with hypertrophy and muscle protein synthesis. Published studies therefore identified ACE-031 as one of the defining research tools within modern ActRIIB pathway biology.
Several investigations have examined ACE-031 within musculoskeletal and body-composition research. A pivotal phase I study in healthy postmenopausal women demonstrated statistically significant increases in lean body mass and thigh-muscle volume alongside improvements in bone-metabolism biomarkers and reductions in fat mass. Additional investigations documented substantial suppression of follicle-stimulating hormone (FSH), confirming activin pathway involvement within reproductive endocrinology.
Research literature has further explored ACE-031 within Duchenne muscular dystrophy and cachexia investigations. Published studies demonstrated trends toward improved lean mass, ambulatory function and bone mineral density in DMD models while additionally identifying vascular safety signals associated with off-target BMP-9 and BMP-10 sequestration. These observations now inform the design of next-generation selective ActRIIB ligand traps with improved specificity profiles.
Scientific investigations additionally documented important applications for ACE-031 within oxidative-metabolism and muscle-fatigability research. Studies confirmed modulation of PGC-1α, PPARβ and PDK4 signalling associated with oxidative fibre metabolism, mitochondrial regulation and skeletal-muscle capillarisation. Research also explored ACE-031 within anti-doping assay development and comparative analyses involving Follistatin 344, MYO-029 and other myostatin-inhibitor systems.
Research institutions and peptide laboratories throughout London, Dublin, Berlin, Stockholm, Copenhagen, Vienna and Amsterdam continue exploring advanced ActRIIB compounds within controlled scientific environments. Interest in myostatin inhibitors and anabolic-signalling pathway compounds continues increasing throughout the UK and European scientific sector as laboratories seek advanced molecules for receptor and pathway analysis.
For researchers seeking additional peptide information and fulfilment experiences, our customer testimonials provide insight into the standards and customer experience offered by Lavish Peptides throughout the UK and Europe.
UK and European Peptide Delivery
Lavish Peptides provides fast and discreet shipping for ACE-031 UK research products throughout England, Scotland, Wales, Northern Ireland, Ireland, France, Germany, Spain, Italy, Belgium, Austria, Portugal, Sweden, Denmark, Poland and the Netherlands.
Researchers throughout London, Manchester, Liverpool, Birmingham, Leeds, Glasgow, Edinburgh, Paris, Berlin, Amsterdam, Madrid, Milan and Rome continue relying on secure peptide fulfilment services and dependable delivery standards when sourcing laboratory compounds online.
Every ACE-031 UK order is packaged carefully to support customer privacy and maintain product integrity throughout transportation. Our fulfilment procedures are designed to support laboratories and research-focused customers seeking efficient peptide sourcing across Europe.
Researchers interested in additional premium peptide compounds may also wish to explore our Follistatin peptide product available through the Lavish Peptides research catalogue.
Storage and Handling Recommendations
ACE-031 UK research proteins should be handled according to appropriate laboratory handling standards and storage procedures. Researchers commonly store lyophilised fusion proteins in cool, dry environments away from direct sunlight and unnecessary temperature fluctuations.
Maintaining controlled storage conditions may help preserve compound integrity during laboratory and analytical applications. Proper laboratory procedures should always be followed during preparation, handling and research activities.
Lavish Peptides recommends reviewing internal laboratory protocols and safe handling standards before working with research compounds within laboratory environments.
Why Researchers Choose Lavish Peptides
Lavish Peptides continues establishing itself as a trusted supplier within the UK and European peptide market by focusing on premium sourcing, third-party verification and professional fulfilment standards.
Researchers choose Lavish Peptides for:
- Premium research-grade peptide sourcing
- Third-party HPLC-verified purity
- Fast UK dispatch
- Discreet packaging
- Reliable EU shipping
- Secure checkout experience
- Responsive customer support
- Laboratory-focused fulfilment standards
Our objective is to provide premium peptide compounds for laboratory and analytical use throughout Europe while maintaining dependable customer support and strict quality expectations.
For laboratory and in vitro research use only. Not for human consumption. Not a medicine.
Reviews
There are no reviews yet.